RPG Life Sciences News and Updates

Pharmaceuticals company RPG Life Sciences announced Q1FY26 results RPG Lifesciences revenue recorded 2.1% YoY increase in sales (18.1% Q-o-Q growth) along with a healthy EBITDA margin of 24.1%. Profit before tax remained largely in line with previous year stood at Rs 35.4 crore in this year vs. Rs 36.0 crore in previous year Year on Year Revenue from Operations stood at Rs 168.9 crore vs. Rs 165.4 crore Ashok Nair, Managing Director, RPG Life Sciences said, “In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach. We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach.” “We are actively exploring inorganic growth opportunities across both formulations and APIs to further accelerate our growth trajectory and create lasting value for all stakeholders,” added Nair. Result PDF

26.58% Gain from 52W Low

RPG Life Sciences News and Updates

Keep track of all breaking news on RPG Life Sciences from all sources in a single place.